The FDA has expanded the approval of Bayer’s Hyrnuo (sevabertinib) to the first-line treatment of HER2-mutated non-small cell lung cancer (NSCLC) — meaning eligible patients can now receive it as their initial therapy, not only after other treatments have failed.
A distinct slice of lung cancer
Most people associate HER2 with breast cancer, but a small subset of lung cancers — on the order of 2–4% of NSCLC cases — are driven by HER2 (ERBB2) activating mutations. These are molecularly distinct tumors, and identifying them requires genomic testing. Historically, patients with HER2-mutant lung cancer had limited targeted options and often defaulted to chemotherapy. The rise of precision oncology — matching drugs to the specific mutation driving a tumor — has gradually changed that, with targeted agents such as the antibody-drug conjugate trastuzumab deruxtecan carving out a role in previously treated disease.
What changed
Sevabertinib is a kinase inhibitor — a targeted oral pill — for adults with locally advanced or metastatic non-squamous NSCLC whose tumors carry HER2 activating mutations, detected by an FDA-authorized test. It had previously been approved only for patients who had already received prior systemic therapy. In this update (dated September 9, 2026), the FDA removed that requirement, opening the door to previously untreated patients — the coveted first-line setting.
The evidence, and the strings attached
The decision was an accelerated approval, based on the single-arm Phase 1/2 SOHO-01 trial, in which 75% of evaluable patients responded (objective response rate, 69 patients). Accelerated approval is a faster pathway that relies on a promising early measure — here, tumor shrinkage — rather than waiting for long-term survival data. The trade-off: continued approval may depend on a confirmatory trial that verifies a real clinical benefit. If that trial disappoints, the approval can be withdrawn.
Why it matters
Moving an effective targeted therapy earlier in treatment can spare some patients a round of chemotherapy and its side effects, and generally, matching the right drug to the right mutation from the start yields better responses. The expansion also intensifies competition in HER2-mutant NSCLC, a small but strategically important niche that several drugmakers are now pursuing. For patients, more first-line options — and the genomic testing needed to identify who qualifies — is unambiguously good news. The broader takeaway: precision oncology continues to fragment lung cancer into ever-smaller, individually targetable subsets. This is regulatory news, not medical advice; treatment choices belong with an oncologist.